Top Page
Innovent Biologics
(1801)
Innovent Biologics (1801) vs. iShares MSCI Hong Kong ETF (EWH)
Innovent Biologics Business Overview & Revenue Model
Innovent Biologics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.42B | 9.42B | 6.21B | 4.56B | 4.27B | 3.84B |
| Gross Profit | 8.72B | 7.91B | 4.40B | 3.63B | 3.70B | 3.46B |
| EBITDA | 660.90M | -480.28M | -660.68M | -1.75B | -2.37B | -704.74M |
| Net Income | 1.13B | -94.63M | -1.03B | -2.18B | -2.73B | -998.42M |
Balance Sheet | ||||||
| Total Assets | 23.59B | 21.60B | 20.63B | 17.59B | 16.24B | 11.83B |
| Cash, Cash Equivalents and Short-Term Investments | 9.54B | 7.88B | 10.97B | 9.17B | 9.02B | 8.12B |
| Total Debt | 3.38B | 2.83B | 3.62B | 3.23B | 2.50B | 1.21B |
| Total Liabilities | 9.17B | 8.48B | 8.10B | 6.86B | 5.91B | 3.06B |
| Stockholders Equity | 14.42B | 13.12B | 12.53B | 10.73B | 10.33B | 8.78B |
Cash Flow | ||||||
| Free Cash Flow | 1.24B | -418.39M | -1.24B | -3.30B | -3.87B | -1.08B |
| Operating Cash Flow | 1.50B | 1.29B | 147.81M | -1.92B | -2.02B | -307.69M |
| Investing Cash Flow | -611.72M | -1.17B | -998.66M | -1.44B | -2.70B | -5.18B |
| Financing Cash Flow | -345.82M | -606.63M | 2.59B | 2.89B | 5.00B | 4.91B |
Innovent Biologics Technical Analysis
Innovent Biologics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$23.44B | 33.55 | 27.37% | ― | 2.57% | 18.79% | |
63 Neutral | HK$146.63B | 10.60 | 9.79% | ― | 16.90% | 63.11% | |
61 Neutral | HK$136.13B | 36.49 | 8.41% | ― | 52.78% | ― | |
54 Neutral | HK$105.70B | 12.76 | 11.72% | 1.40% | 13.69% | 50.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$93.96B | -32.76 | -14.40% | ― | 33.46% | -7.60% | |
38 Underperform | HK$30.62B | -22.62 | -15.06% | ― | 38.56% | 48.26% |
Innovent Biologics Corporate Events
Innovent reported FY2025 product revenue of RMB11.9 billion, up 45% year over year, with fourth-quarter sales climbing over 60% to RMB3.3 billion thanks to six drugs entering the 2026 NRDL and sustained growth from flagship oncology brands. Management highlighted the milestone of surpassing RMB10 billion in annual product revenue as validation of its dual-engine strategy, accelerating uptake of new chronic disease assets, and continued investment in next-generation immuno-oncology, ADC, and CVM candidates to reinforce market leadership and support global expansion.
The most recent analyst rating on (HK:1801) stock is a Hold with a HK$86.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics announced that China’s National Medical Products Administration has approved its CTLA-4 monoclonal antibody TABOSUN (ipilimumab N01 injection) in combination with its PD-1 inhibitor sintilimab as a neoadjuvant treatment for stage IIB–III resectable MSI-H or dMMR colon cancer. The product is the first domestically developed CTLA-4 antibody approved in China and the world’s first CTLA-4 therapy cleared for neoadjuvant use in colon cancer, positioning Innovent at the forefront of dual immune-oncology regimens and potentially reshaping pre-surgical treatment standards for this hard-to-treat subset of patients. The approval, backed by strong pathological complete response data from Phase 1b and pivotal Phase 3 studies showing markedly higher pCR rates without significant added safety risks versus surgery alone, underscores the company’s growing clinical and commercial footprint in immuno-oncology and may reduce reliance on adjuvant chemotherapy for patients with resectable MSI-H/dMMR colon cancer.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$115.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics has announced the inclusion of seven innovative drugs in China’s updated 2025 National Reimbursement Drug List (NRDL), which will be effective from January 1, 2026. This inclusion covers key disease areas such as oncology and cardiovascular diseases, enhancing patient access and affordability. The announcement underscores Innovent’s commitment to providing pioneering treatments and improving healthcare outcomes in China, potentially benefiting a large number of patients and families.
The most recent analyst rating on (HK:1801) stock is a Hold with a HK$101.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics announced the grant of 15,000 share options and 148,200 restricted shares to non-connected employees as part of its 2024 Share Scheme. This move is designed to incentivize employees by aligning their interests with company performance, with vesting tied to individual performance targets. The initiative reflects Innovent’s commitment to fostering a motivated workforce, potentially enhancing its operational efficiency and competitive positioning in the biopharmaceutical industry.
The most recent analyst rating on (HK:1801) stock is a Hold with a HK$101.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics, Inc. has successfully closed a global strategic partnership with Takeda, fulfilling all conditions of their License, Option, and Collaboration Agreement, as well as the Share Issuance Agreement. This resulted in the issuance of 6,913,834 shares, raising approximately HK$778 million in gross proceeds. The transaction enhances Innovent’s strategic positioning and financial resources, allowing further development in their biologic medicines portfolio.
The most recent analyst rating on (HK:1801) stock is a Hold with a HK$101.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics has announced that its new drug, PECONDLE® (picankibart injection), has received approval from China’s National Medical Products Administration for treating moderate-to-severe plaque psoriasis. This approval marks the first domestically developed IL-23p19 monoclonal antibody in China, offering significant benefits such as improved skin clearance and quality of life for patients. The drug’s approval is based on positive results from a Phase 3 clinical study, positioning Innovent as a key player in the evolving psoriasis treatment landscape, which is shifting towards precision therapies.
The most recent analyst rating on (HK:1801) stock is a Hold with a HK$89.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics has announced that China’s National Medical Products Administration has accepted the supplementary application for the 9mg dosage of mazdutide, a dual receptor agonist for weight management in adults with moderate to severe obesity. The acceptance is based on successful Phase 3 clinical trial results, demonstrating significant weight loss and improved cardiometabolic health markers. This development positions Innovent to offer a novel, effective treatment alternative to surgery for obesity in China, potentially impacting the company’s market presence and providing a personalized medical solution for patients.
The most recent analyst rating on (HK:1801) stock is a Hold with a HK$89.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.